JAMA
August 31, 2023
Charles L Raison, Gerard Sanacora, Joshua Woolley et al.
493 citations
A single 25-mg dose of synthetic psilocybin, administered with psychological support, produced a clinically significant and sustained reduction in depressive symptoms and functional disability over 43 days in adults with major depressive disorder. In a phase 2 trial of 104 participants, those receiving psilocybin showed a mean 12.3-point greater improvement on the Montgomery-Asberg Depression Rating Scale at day 43 compared with those receiving a niacin placebo. Psilocybin also improved daily functioning and led to more sustained response, though not remission. No serious adverse events occurred, but psilocybin was associated with more overall and severe adverse events.
JAMA
October 21, 2025
Reid Robison, Robert Barrow, Craig Conant et al.
22 citations
A single dose of MM120 (lysergide D-tartrate) reduces anxiety in a dose-dependent way in adults with moderate to severe generalized anxiety disorder. In a phase 2b randomized, double-blind, placebo-controlled trial with 198 participants, the 100-µg and 200-µg doses produced significantly greater reductions in Hamilton Anxiety Rating Scale scores at 4 weeks than placebo, with differences of -5.0 and -6.0 points, respectively. Lower doses (25 µg and 50 µg) did not differ from placebo. Common side effects included visual perceptual changes and nausea, which increased with dose.
Frontiers in Psychiatry
February 9, 2023
Anya Ragnhildstveit, Miriam Kaiyo, Matthew Brian Snyder et al.
10 citations
A 28-year-old woman with complex dissociative posttraumatic stress disorder (D-PTSD) underwent ten sessions of cannabis-assisted psychotherapy (CAP) over five months, combined with cognitive behavioral therapy. After treatment, her pathological dissociation score, measured by the Multidimensional Inventory of Dissociation, dropped by 98.5%, and she no longer met criteria for D-PTSD. She also experienced reduced cognitive distractibility, less emotional suffering, and improved psychosocial functioning. The patient has maintained these gains for over two years. The authors suggest CAP, which produced subjective effects similar to psychedelics like psilocybin and ketamine, warrants further research as a potential treatment for D-PTSD.
Journal of psychoactive drugs
January 1, 2024
Reid Robison, Madeline Brendle, Claire Moore et al.
Ten frontline healthcare workers with burnout and PTSD symptoms were treated with group ketamine-assisted psychotherapy (KAP) in a private clinic. They attended six weekly sessions: one preparation, three ketamine sessions (two sublingual, one intramuscular), and two integration sessions. PTSD, depression, and anxiety scores improved from pre- to post-treatment, with a 59% reduction in PTSD scores, 58% reduction in depression scores, and 36% reduction in anxiety scores. After treatment, all participants screened negative for PTSD, 90% had minimal or mild depression, and 60% had minimal or mild anxiety. Ketamine was well tolerated with no significant adverse events. Participant feedback supported the improvements.
Journal of eating disorders
May 6, 2022
Reid Robison, Adele Lafrance, Madeline Brendle et al.
In a small case series of five patients with eating disorders and co-occurring mood and anxiety disorders, group-based ketamine-assisted psychotherapy (G-KAP) delivered weekly over four weeks in a residential treatment setting was associated with clinically significant improvements in depression scores (PHQ-9) for four of five participants and in anxiety scores (GAD-7) for two of five participants, measured from before dosing to 24 hours after the final session. No serious adverse events occurred, and the protocol was reported as practical to implement. The findings suggest G-KAP may be a useful adjunct to intensive eating disorder treatment, though further research is needed.
Brain sciences
March 12, 2022
Anya Ragnhildstveit, Matthew Slayton, Laura Kate Jackson et al.
Eating disorders are serious psychiatric conditions with limited treatment options. Ketamine, a drug approved for treatment-resistant depression, is now being investigated for eating disorders. This review examines the evidence for ketamine in treating anorexia nervosa, bulimia nervosa, and binge eating disorder. Results are encouraging but limited to case reports on anorexia nervosa. More research is needed to determine ketamine's effectiveness across different eating disorder types, establish safety, and optimize dosing.